Approval

FDA Considers Revoking Pfizer’s Covid Vaccine Approval for Under-5s: What This Means for Pediatric Health and Pharma Investors

FDA may pull authorization of Pfizer Covid shot for children under 5

Pfizer’s Covid-19 vaccine for healthy children under 5 is on the brink of losing FDA authorization—a development that could reshape pediatric vaccination strategies and ripple through the biotech and healthcare investment landscape. At Extreme Investor … Read more

FDA’s new focus on drug affordability could reshape approval speed—key insight for investors eyeing pharma innovation and market access

Watch CNBC's full interview with FDA commissioner Dr. Marty Makary

The FDA’s New Voucher Program: A Game-Changer for Drug Affordability and Innovation? The Food and Drug Administration (FDA) recently unveiled a bold shift in its drug approval strategy that could reshape the pharmaceutical landscape—and investors … Read more